The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

PROPOSAL FOR RESOLUTION ON AUTHORIZATION REGARDING ISSUES OF WARRANTS

The board of directors of Alligator Bioscience AB, Reg. No. 556597-8201, proposes that the extraordinary general meeting on 27 November 2026 resolves to authorize the board of directors, within the limits set forth in the articles of association, up until the next annual general meeting, at one or several occasions, with deviation from the shareholders' preferential rights resolve to issue warrants. The right to subscribe for the warrants shall be granted solely to Fenja Capital II A/S ("**Fenja Capital**"). The warrants shall be issued free of charge.

The purpose of the authorization and the reasons for the deviation from the shareholders' preferential rights and that the warrants are issued free of charge is to fulfil the company's obligations to Fenja Capital under the loan agreement entered into by the company and Fenja Capital in July 2026 (and as further described in the company's press releases from 23 July 2026 and 29 September 2026). According to the loan agreement, Fenja Capital has received warrants series 2026/2031. The warrants are subject to terms and conditions that contain recalculation terms that entail a so-called "full dilution protection", meaning that Fenja Capital, with certain exceptions, shall be compensated in the event of certain corporate actions so that Fenja Capital always has the right to be allocated additional warrants so that the warrants held by Fenja Capital together entail the same dilution as the warrants represented immediately prior to the corporate action, calculated on the number of outstanding ordinary shares in the company. According to the loan agreement, Fenja Capital also has the right to request recalculation of already issued warrants series 2026/2031, which may require the issuance of new warrants of the same series to replace the already issued warrants.

In light of the upcoming exercise of outstanding warrants series TO 15, which will affect the number of shares in the company, the board of directors assesses that it is in the company's and all shareholders' interest that the board of directors has the flexibility to issue warrants to Fenja Capital in in accordance with the loan agreement.

For a valid resolution, the proposal has to be supported by shareholders representing at least two-thirds of the votes cast as well as of all shares represented at the meeting.

The company's CEO shall be authorized to make the minor formal adjustments of the resolution which may be required for registration with the Swedish Companies Registration Office (*Sw*. Bolagsverket).

Lund in October 2026

The board of directors of Alligator Bioscience AB (publ)